Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

100%(4 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_1

20%

Ph phase_2

60%

Ph phase_3

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

3(60.0%)

Phase 3Large-scale testing

1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(1)

Detailed Status

Completed4

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (20.0%)

Phase 23 (60.0%)

Phase 31 (20.0%)

Trials by Status

terminated120%

completed480%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_3

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

NCT02344303

Clinical Trials (5)

Showing 5 of 5 trials

NCT02656875Phase 3

A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain

Completed

NCT02335294Phase 2

A Study of TRV130 for the Treatment of Pain After Abdominoplasty

Completed

NCT02100748Phase 2

A Study of TRV130 for the Treatment of Pain After Bunionectomy

Completed

NCT02520297Phase 2

A Pilot Study of TRV130 for the Treatment of Fracture Pain

Terminated

NCT02344303Phase 1

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5